Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after ...

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to ...

Don't be surprised (or scared) to see coal tar as an ingredient in your shampoo bottle prescribed by a dermatologist. It is ...

Skin conditions with Parkinson’s disease are common and manageable. By paying attention to these symptoms, patients can ...

Arcutis Biotherapeutics surged as Q3 earnings beat forecasts and Zoryve sales boomed. Click for my updated look at ARQT stock ...

This article was reviewed by Knox Beasley, MD. Exosomes for Hair Loss: Costs, Safety, Efficacy, & Benefits The deeper you ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Arcutis Biotherapeutics has recently seen its consensus analyst price target hold steady at $23.38, even as expectations around its risk profile and growth have shifted slightly. This stability comes ...

It’s Eczema Awareness Month, and dermatologist Dr Bernard Ho explains why this often misunderstood condition is more than ...

New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.

Arcutis achieved earlier-than-expected profitability and continues expanding Zoryve's label for broader indications. Read why ...

Did you wash your hair yesterday but it reeked today Find out why your scalp smells and how to treat it naturally for healthy ...